Law Offices of Gary Martin Hays & Associates
P.C.
75 Ponce De Leon Ave NE Ste 101
Atlanta,
GA 30308(470) 294-1674
www.garymartinhays.com
By ALM Staff | March 23, 2022
This suit was surfaced on Law.com Radar. Read the document here.
By Charles Toutant | March 17, 2022
After finding no live case or controversy before the court, U.S. District Judge Michael Shipp said he could not issue an advisory opinion. "Judicial declarations are not intended to be used as academic instruments clarifying the state of the law in hypothetical scenarios," he said.
By Amanda Bronstad | March 11, 2022
The fees and costs outlined in the $26 billion opioid deal with Johnson & Johnson's Janssen Pharmaceuticals and three distributors are a mix of common benefit fees, contingency fees and payments to the states for outside counsel. One law professor said, "it's not like the lawyers are going to be impoverished."
By ALM Staff | March 8, 2022
This suit was surfaced on Law.com Radar. Read the document here.
By Amanda Bronstad | February 25, 2022
Johnson & Johnson and three drug distributors—AmerisourceBergen, Cardinal Health and McKesson—agreed on Friday to move forward with the second largest multistate settlement in U.S. history after 90% of cities and counties signed up to obtain funds to combat the opioid crisis.
By Amanda Bronstad | February 24, 2022
Drug companies must decide by Friday whether to move forward with, or walk away from, funds that would compensate nearly all 50 states and U.S. territories for costs incurred by the opioid crisis.
By ALM Staff | December 13, 2021
This suit was surfaced by Law.com Radar. Read the document here.
New Jersey Law Journal | Analysis
By Caroline E. Oks | December 9, 2021
The Circuit will once again address its strict ascertainability requirement for class certification in the case 'In re Niaspan Antitrust Litigation.' This appeal represents the first ascertainability case in the Third Circuit that focuses on the pharmaceutical industry and the ability to identify, through expert testimony, who paid for prescription drugs.
By Meghann M. Cuniff | Amanda Bronstad | November 23, 2021
Damages will be determined by the trial judge after later hearings.
By Ross Todd | November 23, 2021
Barbara Mullin of Patterson Belknap Webb & Tyler fended off a generic drug maker's patent challenge to Janssen's antipsychotic drug Invega Sustenna. The win means nearly 10 more years of patent protection for the drug.
Presented by BigVoodoo
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
McCarter & English, LLP, a well established and growing law firm, is actively seeking a talented and driven associate having 2-5 years o...
Gill & Chamas, LLC seeks a Personal Injury attorney to work in their Woodbridge, NJ office. Candidate must possess the following: ...
We are seeking an attorney with a minimum of four years of experience in transactional work to join our well-established, nationally renowne...